Here are some of the steps (greatly simplified) and gaps that can occur in the HIV Treatment Cascade:

Size: px
Start display at page:

Download "Here are some of the steps (greatly simplified) and gaps that can occur in the HIV Treatment Cascade:"

Transcription

1 CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Alberta Reducing deaths by strengthening the HIV Treatment Cascade 20 May 2014 In Canada and other high-income countries, deaths from AIDS-related illnesses have decreased dramatically since the arrival of potent combination anti-hiv therapy (commonly called ART or HAART) in the mid-to-late 1990s. The benefits of ART are so tremendous that researchers in high-income countries expect that young adults who become infected today and who are diagnosed and begin treatment shortly thereafter and are engaged in their care and who do not have serious co-existing health issues are likely to live into their 70s. At the level of a large city or region When taken every day, exactly as directed, ART not only improves a person s health but it also significantly reduces the amount of HIV in the blood and genital fluids. This latter effect can greatly help to reduce the further spread of HIV in a city or region. The spectrum of care For the widespread use of ART to significantly reduce the spread of HIV, people who test positive must have timely and barrier-free access to the medical-healthcare system so that their needs are met. There are many steps that need to happen between getting counselling, HIV testing, starting ART and reaching and maintaining the goal of a low viral load. These steps reflect the spectrum of care and are also called the HIV Treatment Cascade, or simply the Cascade of Care. Here are some of the steps (greatly simplified) and gaps that can occur in the HIV Treatment Cascade: Counselling and screening for HIV Returning for the test result and counselling Agreeing to be referred to a doctor with the skills and knowledge to care for people with HIV Being referred for care after counselling and HIV diagnosis but not visiting the health clinic Attending an initial clinic visit but not having blood drawn for immunologic and virologic assessments Attending an initial clinic visit, having blood drawn and making subsequent clinic visits (retained in care) Being retained in care but not taking ART Being retained in care, initiating ART but being unable to have viral load fall below the lower limit of quantification usually either 50 copies/ml or 40 copies/ml depending on the test available to local labs; viral loads that are below this threshold are commonly called undetectable Being retained in care, initiating ART and achieving a low viral load More focus is being paid to the HIV Treatment Cascade as researchers realize that gaps in the Cascade impair a person s health and contribute to the spread of HIV. Studies of the HIV Treatment Cascade belong to an emerging field of research called Program Science. Unsuccessful engagement with the HIV Treatment Cascade can have serious health implications at the individual level, as researchers in Alberta have recently documented. In that province, a team of researchers has been monitoring what happened to 543 newly diagnosed people with HIV. They have found issues in the HIV Treatment Cascade such as the following:

2 apparent lack of referral for care after an HIV diagnosis despite referrals nearly 18% of newly diagnosed people never visited a clinic to receive care and treatment at least 36 people died and 70% of these deaths were HIV related most deaths occurred in people who did not remain in care This focus on deaths arising from falling out of the Cascade is novel and important because it means that fixing the gaps in the Cascade has the potential to save lives. The Alberta study is a good first step toward documenting the consequences of problems with the Cascade. Further investigation is needed to capture and understand the reasons for some people s disappearance from care and to find ways to narrow gaps in the Cascade, not only in Alberta but in other regions. Study details The Southern Alberta HIV Clinic in Calgary is a major regional treatment centre. People who test positive for HIV in the region are referred to this clinic. Researchers focused on the following outcomes related to the HIV Treatment Cascade: diagnosed with HIV but never referred (or linked) to care referred for HIV care but never visited the HIV clinic made a first visit to the clinic for counselling and registration for care but never made a subsequent visit continued to make clinic visits (retained in care) but did not take ART retained in care and took ART but did not achieve a low viral load (less than 40 copies/ml) The first visit to the clinic helps nurses and social workers develop a relationship with the patient. The clinic staff provides psychosocial support and education about HIV and its treatment, as well as answering questions that the patient might have. After completing the counselling and intake process, the patient provides blood for immunologic and virologic assessment. The Alberta researchers also had access to public health, provincial and clinic databases so they were able to keep track of patients as they moved through the Cascade. Results New infections During the study period 2006 to 2013 there were 543 new and confirmed cases of HIV infection. The researchers stated that overall 12% (65 people) of new HIV diagnoses occurred shortly before, during or shortly after [less than a week of] hospitalization. Note that the Public Health Agency of Canada (PHAC) estimates that approximately 25% of people in Canada who have HIV are not aware of their infection status. Based on this figure, the Alberta researchers calculated that there were likely an additional 137 cases (25% more) of HIV during their study, for a total of 680 confirmed and estimated new infections. However, in our report we will focus on the 543 confirmed cases of new HIV infections. Results From test result to the clinic The researchers found the following: 500 people (92%) of known new cases of HIV were referred for care to the clinic 43 people (8%) of newly diagnosed cases and who were known to the regional Public Health Department were not referred for care (possible reasons for this are explored later in this report) Results In the clinic 412 people (82% of 500) who were referred to the clinic remained in care. These 412 people represented 76% of the confirmed new infections and they were monitored for an average of five years. Additionally, among the patients in care, the proportions on ART and having a low viral load were as follows: most patients (88%) received ART 76% of patients on ART had a viral load less than 40 copies/ml by the end of the study

3 Researchers gave the following reasons for those patients not on ART: they had a high CD4+ cell count they had a viral load less than 40 copies/ml it was the patients own personal choice Distribution and causes of death The researchers noted that a total of 36 deaths occurred among people diagnosed with HIV during the study. They stated that only one death occurred [among new cases of HIV] that was not linked to care in any form. This single case was only recognized to have HIV after death. The remaining 35 deaths occurred in people who at one time had been linked to care but did not remain in care. Here are further details about those deaths: 57% (20 of 35 deaths) occurred in people who were referred to or connected to the clinic but did not make regular visits to the clinic. These people did not receive ART and in some cases did not have their blood drawn for immunologic and virologic assessment. 70% of these 20 deaths (14 of 20 people) were AIDS-related six of these 20 deaths occurred in people who were hospitalized. Five of the 14 deaths that occurred outside of hospitalization were among patients who had an initial clinic visit to meet with a nurse or social worker but who did not return for their first appointment with a physician. Deaths in care Among participants who were in care (and who stayed in care), only one person died without having ever received ART. According to the study team, he chose not to initiate therapy. Five of 14 people who died initially received ART; however, prior to their death they had stopped taking ART. In four of these five cases, participants chose to discontinue taking ART. Researchers found that people who died while in care were more likely to have the following profile compared to people who survived: Overall low CD4+ counts (63 cells vs. nearly 300 cells) an additional pre-existing illness or co-morbidity (46% vs. 14%) HIV risk factor was sharing equipment for injecting street drugs (27% vs. 7%) older at the time of HIV diagnosis (47 years vs. 37 years) In the present study, over a period of six years, 92% of newly diagnosed HIV cases were linked to care. However, only 58% of people who began ART eventually had their viral load fall below the 40-copy/ml mark. These figures are disappointing and are likely lower than needed to significantly impact [the spread of HIV in Southern Alberta], the researchers stated. Importantly, the researchers noted that they also found that a significant proportion of deaths occurred after initial linkage [to a clinic] but before full engagement to care. The researchers advanced the following reasons that patients were not able to link to care: in cases of HIV testing, some people may not have returned to receive their results and their physician or Public Health department was unable to contact them patients may have ignored the positive test result some patients may have moved and could not be found Additional research is needed about these and other reasons that patients fall out of the medical-healthcare system. Clues about this may come from another study by the U.S. Centres for Disease Control and Prevention (CDC).

4 The Never in Care Study The CDC has also been concerned about people who do not connect with the healthcare system after a positive HIV test result. As part of an investigation called the Never in Care Study, the CDC found that contacting people who test positive for subsequent interviews is a problem because it can be difficult to locate them. In particular, the CDC and public health officials cited the following reason: Contact information obtained at the time of HIV diagnosis was frequently incorrect. Furthermore, even when researchers were able to locate people, nearly 30% refused to be interviewed. Among 132 people who had been diagnosed with HIV within the past four to 24 months and who consented to be interviewed by the CDC as part of a study, here are some of the reasons that they gave for not entering care: 55% not wanting to think about HIV 55% feeling healthy 45% feeling depressed 43% not wanting to disclose their HIV status According to the CDC researchers, most participants gave multiple reasons for not entering care. The CDC concluded that poverty and mental health problems may be contributing factors, underscoring the importance of supportive services to help with starting and staying in care. Several studies examine gaps in care Researchers in BC have also documented gaps in the HIV Treatment Cascade. The Alberta study has extended the BC findings by highlighting the serious consequences that such gaps pose to people living with HIV. These gaps show that receipt of a positive HIV test result is not necessarily followed by linkage to care, retention in care and successful use of ART. The results from Alberta and BC will hopefully encourage researchers in other regions of Canada to investigate and publish their findings of the HIV Treatment Cascade. By uncovering gaps in the Cascade, researchers can underscore the need for resources to be applied to the spectrum of care so that gaps can be closed, the health of HIV-positive people can improve, and the spread of HIV in Canada can be greatly diminished. Resources Gaps in British Columbia s HIV Treatment Cascade CATIE News The HIV Treatment Cascade patching the leaks to improve HIV prevention Prevention in Focus Treatment as prevention: Do the individual prevention benefits translate to the population level? Prevention in Focus Acknowledgement We thank infectious disease specialist John Gill, MD, for his helpful review, discussion and research assistance. REFERENCES: Sean R. Hosein 1. May MT, Gompels M, Delpech V, et al. Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy: UK cohort study. AIDS. 2014;28: Samji H, Cescon A, Hogg RS, et al. Closing the Gap: Increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS One Dec 18;8(12):e Sabin CA. Do people with HIV infection have a normal life expectancy in the era of combination antiretroviral therapy? BMC Medicine Nov 27;11: Kitahata MM, Van Rompaey SE, Shields AW. Physician experience in the care of HIV-infected persons is associated with earlier adoption of new antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes Jun 1;24(2):

5 5. Kitahata MM, Koepsell TD, Deyo RA, et al. Physicians experience with the acquired immunodeficiency syndrome as a factor in patients survival. New England Journal of Medicine Mar 14;334(11): Nosyk B, Montaner JSG, Colley G et al. The cascade of HIV care in British Columbia, Canada, : a population-based retrospective cohort study. Lancet Infectious Diseases Jan;14(1): McNairy ML, El-Sadr WM. Antiretroviral therapy for the prevention of HIV transmission: what will it take? Clinical Infectious Diseases Apr;58(7): Mugavero MJ, Amico KR, Horn T, Thompson MA. The state of engagement in HIV care in the United States: from cascade to continuum to control. Clinical Infectious Diseases Oct;57(8): Krentz HB, MacDonald J, Gill MJ. High mortality among HIV-infected individuals before accessing or linking to HIV care: a missing outcome in the Cascade of Care. Open Forum Infectious Diseases. 2014; in press. 10. Bertolli J, Garland PM, Valverde EE, et al. Missed connections: HIV-infected people never in care. Public Health Reports Mar-Apr;128(2):

6 Produced By: 555 Richmond Street West, Suite 505, Box 1104 Toronto, Ontario M5V 3B1 Canada Phone: Toll-free: Fax: Charitable registration number: RR Disclaimer Decisions about particular medical treatments should always be made in consultation with a qualified medical practitioner knowledgeable about HIV- and hepatitis C-related illness and the treatments in question. CATIE provides information resources to help people living with HIV and/or hepatitis C who wish to manage their own health care in partnership with their care providers. Information accessed through or published or provided by CATIE, however, is not to be considered medical advice. We do not recommend or advocate particular treatments and we urge users to consult as broad a range of sources as possible. We strongly urge users to consult with a qualified medical practitioner prior to undertaking any decision, use or action of a medical nature. CATIE endeavours to provide the most up-to-date and accurate information at the time of publication. However, information changes and users are encouraged to ensure they have the most current information. Users relying solely on this information do so entirely at their own risk. Neither CATIE nor any of its partners or funders, nor any of their employees, directors, officers or volunteers may be held liable for damages of any kind that may result from the use or misuse of any such information. Any opinions expressed herein or in any article or publication accessed or published or provided by CATIE may not reflect the policies or opinions of CATIE or any partners or funders. Information on safer drug use is presented as a public health service to help people make healthier choices to reduce the spread of HIV, viral hepatitis and other infections. It is not intended to encourage or promote the use or possession of illegal drugs. Permission to Reproduce This document is copyrighted. It may be reprinted and distributed in its entirety for non-commercial purposes without prior permission, but permission must be obtained to edit its content. The following credit must appear on any reprint: This information was provided by CATIE (the Canadian AIDS Treatment Information Exchange). For more information, contact CATIE at CATIE Production of this content has been made possible through a financial contribution from the Public Health Agency of Canada. Available online at:

Northern Alberta preventing HIV transmission to babies

Northern Alberta preventing HIV transmission to babies CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Northern Alberta preventing HIV transmission to babies 25 June 2009 Since 1996 the widespread availability of combination therapy for HIV

More information

From Safer Sex Guide. Using condoms

From Safer Sex Guide. Using condoms From Safer Sex Guide Using condoms Click to enlarge Using condoms correctly and consistently can signifiantly reduce your chances of passing or getting HIV and other STIs. There are two types of condoms

More information

Viral infections Hep C and HIV linked to hip fractures

Viral infections Hep C and HIV linked to hip fractures CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Viral infections Hep C and HIV linked to hip fractures 22 November 2012 Infection with hepatitis C virus (HCV) and HIV causes inflammation,

More information

Long-acting drugs for HIV

Long-acting drugs for HIV From TreatmentUpdate 222 Long-acting drugs for HIV Long-acting formulations of two anti-hiv drugs are being tested in clinical trials: cabotegravir an experimental integrase inhibitor made available in

More information

Patient navigators for hepatitis C patients found useful in New York City

Patient navigators for hepatitis C patients found useful in New York City CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Patient navigators for hepatitis C patients found useful in New York City 4 January 2017 Hepatitis C virus (HCV) infects and injures the

More information

Exploring the risks of liver cancer after successful treatment for hepatitis C virus

Exploring the risks of liver cancer after successful treatment for hepatitis C virus CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Exploring the risks of liver cancer after successful treatment for hepatitis C virus 11 June 2013 In Canada and other high-income countries,

More information

Detailed results from the START study

Detailed results from the START study From TreatmentUpdate 210 Detailed results from the START study Researchers in 35 countries across all continents collaborated to recruit 4,685 HIV-positive adults who were in good health for START. Upon

More information

Study finds PEP not 100% effective in preventing HIV infection

Study finds PEP not 100% effective in preventing HIV infection From TreatmentUpdate 152 Study finds PEP not 100% effective in preventing HIV infection Some doctors and nurses who care for PHAs may sustain needle-stick injuries. This raises the possibility that they

More information

Hepatitis C treatment program improves access to housing, income and healthcare

Hepatitis C treatment program improves access to housing, income and healthcare CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Hepatitis C treatment program improves access to housing, income and healthcare 13 July 2015 Despite high rates of hepatitis C virus (HCV)

More information

Understanding risk by sex act

Understanding risk by sex act From Safer Sex Guide Understanding risk by sex act Kissing (with tongue) Chlamydia Avoid kissing if you or your partners have sores on the lips or mouth, or if one of you has an active oral infection (such

More information

The debut of velpatasvir for hepatitis C

The debut of velpatasvir for hepatitis C CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. The debut of velpatasvir for hepatitis C 23 November 2015 Hepatitis C virus (HCV) can be grouped into six major strains, or genotypes,

More information

How are testing technologies used to diagnose HIV infection?

How are testing technologies used to diagnose HIV infection? HIV testing technologies are used to determine if a person has HIV. Several types of HIV testing technologies are used in Canada. These tests differ in several ways, including where the test is conducted,

More information

A study about switching from TDF to TAF

A study about switching from TDF to TAF From TreatmentUpdate 211 A study about switching from TDF to TAF Researchers enrolled HIV-positive participants who were taking regimens containing TDF (tenofovir disoproxil fumarate), the original formulation

More information

Doravirine vs. darunavir

Doravirine vs. darunavir From TreatmentUpdate 220 Doravirine vs. darunavir Doravirine is an experimental non-nuke that is undergoing phase III clinical trials. It is designed to be effective against most strains of HIV that are

More information

The epidemiology of HIV in Canada

The epidemiology of HIV in Canada FACTSHEET The epidemiology of HIV in Canada This fact sheet provides a snapshot of the HIV epidemic in Canada. It is one of a series of fact sheets on the epidemiology of HIV and hepatitis C in Canada.

More information

Norwegian HIV vaccine Very modest results seen in recent clinical trial

Norwegian HIV vaccine Very modest results seen in recent clinical trial CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Norwegian HIV vaccine Very modest results seen in recent clinical trial 21 February 2012 Although HIV infection can be treated with combination

More information

Limiting the spread of hepatitis C virus with Treatment as Prevention (TasP)

Limiting the spread of hepatitis C virus with Treatment as Prevention (TasP) From TreatmentUpdate 197 Limiting the spread of hepatitis C virus with Treatment as Prevention (TasP) The idea of Treatment as Prevention, or TasP, has been proposed and is being implemented in some regions

More information

Post-exposure prophylaxis (PEP)

Post-exposure prophylaxis (PEP) Post-exposure prophylaxis (PEP) Summary Post-exposure prophylaxis, or PEP, is a way to help prevent the transmission of HIV in an HIV-negative person who may have been recently exposed to HIV. It involves

More information

The epidemiology of hepatitis C in Canada

The epidemiology of hepatitis C in Canada The epidemiology of hepatitis C in Canada FACT SHEET Published 2017 This fact sheet provides a snapshot of the hepatitis C epidemic in Canada. It is one of a series of fact sheets providing epidemiological

More information

HIV testing technologies

HIV testing technologies HIV testing technologies HIV testing technologies are used to determine if a person has HIV. Several types of HIV testing technologies are used in Canada. These tests differ in several ways, including

More information

American Academy of Pediatrics issues statement on infant feeding and HIV transmission

American Academy of Pediatrics issues statement on infant feeding and HIV transmission CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. American Academy of Pediatrics issues statement on infant feeding and HIV transmission 7 February 2013 The widespread availability of potent

More information

Increased risk for dialysis found with HIV infection

Increased risk for dialysis found with HIV infection CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Increased risk for dialysis found with HIV infection 12 September 2013 In high-income countries such as Canada, Australia and the U.S.

More information

Study finds sustained-release dexamfetamine is promising for reducing cocaine use

Study finds sustained-release dexamfetamine is promising for reducing cocaine use CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Study finds sustained-release dexamfetamine is promising for reducing cocaine use 27 April 2016 Depending on the circumstances, the use

More information

Is there a link between niacin and stroke?

Is there a link between niacin and stroke? CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Is there a link between niacin and stroke? 7 July 2011 A large American-Canadian study called Aim-High was halted 18 months ahead of schedule.

More information

Key messages on hepatitis A for clients are available at the end of this fact sheet.

Key messages on hepatitis A for clients are available at the end of this fact sheet. Hepatitis A Summary Hepatitis A is an infection caused by a virus that can be sexually transmitted. Infection with hepatitis A results in inflammation of the liver (hepatitis). Hepatitis A is transmitted

More information

Hepatitis A FACTSHEET. Summary. What is hepatitis A?

Hepatitis A FACTSHEET. Summary. What is hepatitis A? FACTSHEET Hepatitis A Summary Hepatitis A is an infection caused by a virus that can be sexually transmitted. Infection with hepatitis A results in inflammation of the liver (hepatitis). Hepatitis A is

More information

HIV and the immune system linked to heart disease in women

HIV and the immune system linked to heart disease in women CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. HIV and the immune system linked to heart disease in women 26 September 2013 The widespread availability of potent combination anti-hiv

More information

Study explores risk for shingles in the current era

Study explores risk for shingles in the current era CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Study explores risk for shingles in the current era 19 February 2015 Infection with VZV (varicella zoster virus), a member of the herpes

More information

Superbug increasing among HIV positive people

Superbug increasing among HIV positive people CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Superbug increasing among HIV positive people 24 September 2007 Bacteria are a common source of problems, causing a variety of infections,

More information

Does syphilis affect HIV in the brain?

Does syphilis affect HIV in the brain? CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Does syphilis affect HIV in the brain? 1 February 2011 Outbreaks of sexually transmitted infections (STIs) are occurring in Canada and

More information

Pre-exposure prophylaxis (PrEP)

Pre-exposure prophylaxis (PrEP) FACTSHEET Pre-exposure prophylaxis (PrEP) Summary Pre-exposure prophylaxis, or PrEP, is a way for an HIV-negative person who is at risk of HIV infection to reduce their risk of becoming infected with HIV.

More information

Hep C treatment can cure a person from Hep C. However, a person could get infected again.

Hep C treatment can cure a person from Hep C. However, a person could get infected again. Sofosbuvir (Sovaldi) Summary Sofosbuvir is a medication used to treat Hep C. It is used in combination with other medications to cure people of the Hep C virus. Sofosbuvir is taken at a dose of 400 mg

More information

Programming Connection

Programming Connection The H.E.R. Pregnancy Program Programming Connection Case Study Organization: Streetworks Region: Edmonton, Alberta Prepared: 2018 Quick Facts Population Street involved, Women Date Started 2011 Region

More information

Will de-simplification of HIV treatment become common in highincome

Will de-simplification of HIV treatment become common in highincome CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Will de-simplification of HIV treatment become common in highincome countries? 13 February 2018 As more people start HIV treatment, researchers

More information

The HIV testing process

The HIV testing process FACTSHEET The HIV testing process Summary There are a few steps that a person will take in the HIV testing process. To access an HIV test, people can request a test or may be offered a test. There are

More information

THE POWER OF UNDETECTABLE. What you need to know about HIV treatment as prevention

THE POWER OF UNDETECTABLE. What you need to know about HIV treatment as prevention THE POWER OF UNDETECTABLE What you need to know about HIV treatment as prevention CONTENTS 3 Treatment as prevention First, a few basics: What is an undetectable viral load? How do I know if I m undetectable?

More information

Hepatitis C Basics. Michael Bailey Director of Programming, CATIE. Mary Choy Regional Health Education Coordinator, CATIE

Hepatitis C Basics. Michael Bailey Director of Programming, CATIE. Mary Choy Regional Health Education Coordinator, CATIE Hepatitis C Basics Michael Bailey Director of Programming, CATIE Mary Choy Regional Health Education Coordinator, CATIE CATIE Our History Learning Objectives 1) To learn about the basics of hepatitis C

More information

It is a good idea for anyone having sex to get tested regularly and treated for STIs if necessary.

It is a good idea for anyone having sex to get tested regularly and treated for STIs if necessary. FACTSHEET Sexually Transmitted Infections and HIV Transmission This is one of a series of fact sheets about the biology of HIV transmission. The fact sheets review specific biological factors that make

More information

Does tenofovir (TDF) cause liver injury?

Does tenofovir (TDF) cause liver injury? CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Does tenofovir (TDF) cause liver injury? 10 February 2016 Tenofovir is an important antiviral drug used to treat HIV and hepatitis B virus

More information

Exploring risks for MRSA infection A tale of two studies

Exploring risks for MRSA infection A tale of two studies CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Exploring risks for MRSA infection A tale of two studies 2 March 2012 A group of bacteria called S. aureus (Staphylococcus aureus ) are

More information

Can metformin also protect arteries?

Can metformin also protect arteries? CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Can metformin also protect arteries? 8 December 2011 Reports suggest that cardiovascular disease is becoming common among HIV-positive

More information

Can mirtazapine assist recovery from crystal meth addiction?

Can mirtazapine assist recovery from crystal meth addiction? CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Can mirtazapine assist recovery from crystal meth addiction? 20 December 2011 Stimulants such as amphetamine and its more potent form,

More information

The Patient as Partner

The Patient as Partner From The Positive Side, Summer 2018 The Patient as Partner The idea that a person should be an active participant, not just a recipient, of their own healthcare has deep roots. Feminists, people living

More information

Starting points. living with HIV

Starting points. living with HIV Starting points living with HIV Have you found out you have HIV and are trying to get your bearings? We can help you with the basics of living with HIV. Here s what you ll read about in this booklet: What

More information

3TC (lamivudine, Epivir)

3TC (lamivudine, Epivir) 3TC (lamivudine, Epivir) Summary 3TC is a type of antiretroviral drug called a nucleoside analogue (or nuke ). 3TC can cause nausea, headache, diarrhea, vomiting and weakness; however, it causes few side

More information

Exciting results in monkeys lead to a clinical trial in humans

Exciting results in monkeys lead to a clinical trial in humans From TreatmentUpdate 219 Exciting results in monkeys lead to a clinical trial in humans A close relative of HIV called SIV (simian immunodeficiency virus) causes an AIDS-like disease in susceptible monkeys.

More information

Raltegravir (Isentress)

Raltegravir (Isentress) Raltegravir (Isentress) Summary Raltegravir is a type of anti-hiv drug called an integrase inhibitor. Raltegravir is generally well tolerated. Common side effects include diarrhea, nausea and headache;

More information

Lymphoma FACTSHEET. Summary. About the lymphatic system. Who is at risk for lymphoma? What is lymphoma?

Lymphoma FACTSHEET. Summary. About the lymphatic system. Who is at risk for lymphoma? What is lymphoma? FACTSHEET Lymphoma Summary Lymphoma is a cancer that affects a part of the immune system called the lymphatic system. Like any cancer, the earlier lymphoma is diagnosed, the easier it is to treat. In general,

More information

Schizophrenia and HIV Study underscores serious issues associated with dual diagnoses

Schizophrenia and HIV Study underscores serious issues associated with dual diagnoses CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Schizophrenia and HIV Study underscores serious issues associated with dual diagnoses 15 July 2015 Several studies have found that some

More information

Hepatitis C virus some background information

Hepatitis C virus some background information From TreatmentUpdate 167 Hepatitis C virus some background information Hepatitis C virus (HCV) is spread by exposure to infected blood. The following behaviours, which can expose a person to infected blood,

More information

HIV treatment and an undetectable viral load to prevent HIV transmission

HIV treatment and an undetectable viral load to prevent HIV transmission HIV treatment and an undetectable viral load to prevent HIV transmission FACT SHEET Published 2018 CONTACT US Summary It is now well known that the use of HIV treatment not only improves the health of

More information

Harvoni (ledipasvir + sofosbuvir)

Harvoni (ledipasvir + sofosbuvir) FACTSHEET Harvoni (ledipasvir + sofosbuvir) Summary Harvoni is a medication used to treat hepatitis C. It is approved in Canada for people with genotype 1 hepatitis C virus. Harvoni is a combination of

More information

The elusive AIDS vaccine

The elusive AIDS vaccine CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. The elusive AIDS vaccine 4 March 2008 In the 25 years since HIV was discovered, researchers have made many strides in the fight against

More information

3TC (lamivudine, Epivir)

3TC (lamivudine, Epivir) FACTSHEET 3TC (lamivudine, Epivir) Summary 3TC is a type of antiretroviral drug called a nucleoside analogue (or nuke ). 3TC can cause nausea, headache, diarrhea, vomiting and weakness; however, it causes

More information

Daclatasvir (Daklinza)

Daclatasvir (Daklinza) Daclatasvir (Daklinza) Summary Daclatasvir (Daklinza) is a medication used to treat hepatitis C. It is taken with sofosbuvir (Sovaldi) and sometimes ribavirin. This combination is approved in Canada for

More information

Quad (Stribild) Safety and effectiveness issues in depth

Quad (Stribild) Safety and effectiveness issues in depth From TreatmentUpdate 191 Quad (Stribild) Safety and effectiveness issues in depth The FDA reviewed health-related information collected from 1,408 HIV-positive people who participated in two pivotal clinical

More information

HIV POSITIVE YOUTH: LINKAGE & RETENTION IN CARE

HIV POSITIVE YOUTH: LINKAGE & RETENTION IN CARE HIV POSITIVE YOUTH: LINKAGE & RETENTION IN CARE Site C Youth clinic HIV care pathway DAY 1 Test HIV + PIMA point of care CD4 count in in 3-5 days initiation + in session 3 session 4 1 month Youth Club

More information

Harvoni (ledipasvir + sofosbuvir)

Harvoni (ledipasvir + sofosbuvir) Harvoni (ledipasvir + sofosbuvir) Summary Harvoni is a medication used to treat hepatitis C. It is approved in Canada for people with all genotypes of the hepatitis C virus. Harvoni is a combination of

More information

HPV, Cervical Dysplasia and Cancer

HPV, Cervical Dysplasia and Cancer FACTSHEET HPV, Cervical Dysplasia and Cancer Summary Cervical dysplasia is an abnormal change in the cells of the cervix in the uterus. Early changes, called low-grade lesions by doctors, may persist and

More information

IMPORTANT THINGS TO KNOW WHEN YOU HAVE HEPATITIS C

IMPORTANT THINGS TO KNOW WHEN YOU HAVE HEPATITIS C IMPORTANT THINGS TO KNOW WHEN YOU HAVE HEPATITIS C GETTING STARTED: Important things to know when you have hepatitis C If you just found out that you have hepatitis C, you may have a lot of questions.

More information

Crystal meth interviews reveal its impact on HIV positive men

Crystal meth interviews reveal its impact on HIV positive men CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Crystal meth interviews reveal its impact on HIV positive men 15 April 2009 Crystal meth, also known as ice or Tina, is a form of the stimulant

More information

MG an emerging sexually transmitted infection

MG an emerging sexually transmitted infection CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. MG an emerging sexually transmitted infection 9 October 2013 The bacterium Mycoplasma genitalium (MG) is sexually transmitted and can cause

More information

Tuberculosis FACT SHEET. Summary. What is TB?

Tuberculosis FACT SHEET. Summary. What is TB? Tuberculosis Summary Tuberculosis (TB) is caused by bacteria called Mycobacterium tuberculosis complex and usually affects the lungs. However, among people co-infected with TB and HIV, parts of the body

More information

STOP HIV/AIDS Pilot Project

STOP HIV/AIDS Pilot Project STOP HIV/AIDS Pilot Project QUARTERLY INDICATORS REPORT: 1 April through 30 June 2011 () SUBMITTED TO: The BC Ministry of Health Services SUBMITTED BY: Dr. Rolando Barrios, Dr. Mark Gilbert, Dr. Kate Health,

More information

Care Coach Collaborative Model Bridging Gap of Medical Linkage for HIV Positive Inmates Go home, kiss your Mother, and come into our offices. (Patsy F

Care Coach Collaborative Model Bridging Gap of Medical Linkage for HIV Positive Inmates Go home, kiss your Mother, and come into our offices. (Patsy F Care Coach Collaborative Model Bridging Gap of Medical Linkage for HIV Positive Inmates Go home, kiss your Mother, and come into our offices. (Patsy Fitzgerald) 93% of participants in the Care Coach program

More information

Hints of a cure the future of stem cell transplants and HIV

Hints of a cure the future of stem cell transplants and HIV CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Hints of a cure the future of stem cell transplants and HIV 21 December 2010 In 2008 a team of cancer researchers from Berlin, Germany,

More information

The forgotten group: a new HIV outbreak amongst people who inject drugs. Patricia Anderson Lead CNS BBV Brownlee Centre

The forgotten group: a new HIV outbreak amongst people who inject drugs. Patricia Anderson Lead CNS BBV Brownlee Centre The forgotten group: a new HIV outbreak amongst people who inject drugs Patricia Anderson Lead CNS BBV Brownlee Centre No conflicts to declare Potted History 1981 Modern wave of drug misuse Glasgow soared

More information

Daclatasvir (Daklinza)

Daclatasvir (Daklinza) FACTSHEET Daclatasvir (Daklinza) Summary Daclatasvir (Daklinza) is a medication used to treat hepatitis C. It is taken with sofosbuvir (Sovaldi) and sometimes ribavirin. This combination is approved in

More information

Cascade of medical care to HIV-infected patients in Europe. Cristina Mussini

Cascade of medical care to HIV-infected patients in Europe. Cristina Mussini Cascade of medical care to HIV-infected patients in Europe Cristina Mussini UNAIDS: New HIV treatment target 90% of people tested 90% of people diagnosed with HIV on treatment 90% of people on treatment

More information

PROJECT BRIDGE: Differentiation of HIV Services for PWID in Harm Reduction Programs in Kazakhstan. Nabila El-Bassel, PhD Columbia University

PROJECT BRIDGE: Differentiation of HIV Services for PWID in Harm Reduction Programs in Kazakhstan. Nabila El-Bassel, PhD Columbia University PROJECT BRIDGE: Differentiation of HIV Services for PWID in Harm Reduction Programs in Kazakhstan Nabila El-Bassel, PhD Columbia University CUGH Conference March 16-18, 2018 New York, NY @NabilaElBassel

More information

Financial Incentives, Linkage to Care and Viral Suppression HPTN 065 (TLC-Plus) Study. Wafaa El-Sadr ICAP at Columbia University New York, NY

Financial Incentives, Linkage to Care and Viral Suppression HPTN 065 (TLC-Plus) Study. Wafaa El-Sadr ICAP at Columbia University New York, NY Financial Incentives, Linkage to Care and Viral Suppression HPTN 065 (TLC-Plus) Study Wafaa El-Sadr ICAP at Columbia University New York, NY Outline of Presentation Background and study rationale Methods

More information

STOP HIV/AIDS Pilot Project

STOP HIV/AIDS Pilot Project STOP HIV/AIDS Pilot Project QUARTERLY INDICATORS REPORT: 1 January through 31 March 2012 () SUBMITTED TO: The BC Ministry of Health SUBMITTED BY: Dr. Mark Gilbert and Dr. Kate Heath On behalf of The STOP

More information

Treatment as Prevention

Treatment as Prevention Treatment as Prevention The Key to an AIDS-Free Generation Julio Montaner MD, DSc(hon), FRCPC, FCCP, FRSC, OBC Director, BC-Centre for Excellence in HIV/AIDS, Providence Health Care Professor of Medicine

More information

Health Interventions in Ambulatory Cancer Care Centres DRAFT. Objectives. Methods

Health Interventions in Ambulatory Cancer Care Centres DRAFT. Objectives. Methods ENVIRONMENTAL SCAN Health Interventions in Ambulatory Cancer Care Centres Context Cancer, a complex, chronic condition, will affect an estimated two in five Canadians in their lifetime. 1 Cancer requires

More information

Safe Generations Harnessing Implementation Science to Assess the Impact of Option B+ in Swaziland

Safe Generations Harnessing Implementation Science to Assess the Impact of Option B+ in Swaziland Safe Generations Harnessing Implementation Science to Assess the Impact of Option B+ in Swaziland Background and Rationale In 2015, the World Health Organization (WHO) endorsed universal treatment for

More information

Tuberculosis FACTSHEET. Summary. What is TB?

Tuberculosis FACTSHEET. Summary. What is TB? FACTSHEET Tuberculosis Summary Tuberculosis (TB) is caused by bacteria called Mycobacterium tuberculosis complex and usually affects the lungs. However, among people co-infected with TB and HIV, parts

More information

Community Health Workers (CHWs) in HIV Services: Insights from Virginia. November 16, 2017

Community Health Workers (CHWs) in HIV Services: Insights from Virginia. November 16, 2017 Community Health Workers (CHWs) in HIV Services: Insights from Virginia November 16, 2017 1 Welcome Allyson Baughman, MPH Program Manager, Center for Innovation in Social Work and Health Boston University

More information

MANITOBA HIV REPORT 2015

MANITOBA HIV REPORT 2015 MANITOBA HIV REPORT 2015 The Manitoba HIV Program provides information, specialized care, treatment, and support to approximately 1,250 people living with HIV across the province. The Program has two Winnipeg-based

More information

Hepatitis B FACTSHEET. Summary

Hepatitis B FACTSHEET. Summary FACTSHEET Hepatitis B Summary Hepatitis B is an infection caused by a virus that can be transmitted by sexual exposure to blood or bodily fluids, injection drug use, and household contact with someone

More information

HPV, anal dysplasia and anal cancer

HPV, anal dysplasia and anal cancer HPV, anal dysplasia and anal cancer Summary Anal cancer typically develops over a period of years, beginning with a precancerous condition called anal dysplasia. Anal dysplasia occurs when clusters of

More information

STOP HIV/AIDS Semi-Annual Monitoring Report

STOP HIV/AIDS Semi-Annual Monitoring Report STOP HIV/AIDS Semi-Annual Monitoring Report S2 (July 1, 2013 December 31, 2013) Ellen Demlow 1, Tim Chu 1, Dr. Reka Gustafson 2, Dr. Jat Sandhu 1 1 Public Health Surveillance Unit 2 Communicable Disease

More information

Introduction to the POWER Study Chapter 1

Introduction to the POWER Study Chapter 1 ONTARIO WOMEN S HEALTH EQUITY REPORT Introduction to the POWER Study Chapter 1 AUTHORS Susan K. Shiller, MSc Arlene S. Bierman, MD, MS, FRCPC INSIDE Why do we need a Women s Health Equity Report in Ontario?

More information

Saskatchewan HIV Strategy: Social Network Approach

Saskatchewan HIV Strategy: Social Network Approach Saskatchewan HIV Strategy: Social Network Approach Dr. Johnmark Opondo MHO Provincial Leadership Team (PLT) CATIE Forum: New Science, New Directions in HIV and HCV September 18, 2013 Toronto, Canada A

More information

Antiviral medications can reduce the severity and frequency of genital herpes outbreaks.

Antiviral medications can reduce the severity and frequency of genital herpes outbreaks. Genital herpes Summary Genital herpes is a sexually transmitted infection caused by the herpes simplex virus type 1 (HSV-1) or type 2 (HSV-2). Once a person is infected with HSV, the virus stays in the

More information

IDU Outreach Project. Program Guidelines

IDU Outreach Project. Program Guidelines Ministry of Health and Long-Term Care Ministère de la Santé et des Soins de longue dureé Prepared by: AIDS Bureau Revision Date: April 2001 TABLE OF CONTENTS 1 Introduction...1 1.1 Program Goals... 2 1.2

More information

Descovy FACTSHEET. Summary. What is Descovy? How does Descovy work?

Descovy FACTSHEET. Summary. What is Descovy? How does Descovy work? FACTSHEET Descovy Summary Descovy is the name given to a pill containing the following two anti- HIV drugs: TAF (tenofovir alafenamide) and FTC (emtricitabine). Descovy comes in two, colour-coded strengths

More information

STRENGTHENING THE COORDINATION, DELIVERY AND MONITORING OF HIV AND AIDS SERVICES IN MALAWI THROUGH FAITH-BASED INSTITUTIONS.

STRENGTHENING THE COORDINATION, DELIVERY AND MONITORING OF HIV AND AIDS SERVICES IN MALAWI THROUGH FAITH-BASED INSTITUTIONS. STRENGTHENING THE COORDINATION, DELIVERY AND MONITORING OF HIV AND AIDS SERVICES IN MALAWI THROUGH FAITH-BASED INSTITUTIONS. Acknowledgements This project was fully funded by Center For Disease Control

More information

Implementation of testing (and other interventions along the Continuum of Care)

Implementation of testing (and other interventions along the Continuum of Care) Implementation of testing (and other interventions along the Continuum of Care) Jonathan Mermin, MD, MPH National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention U.S. Centers for Disease Control

More information

Management of AIDS/HIV Infected Healthcare Workers Policy

Management of AIDS/HIV Infected Healthcare Workers Policy Management of AIDS/HIV Infected Healthcare Workers Policy DOCUMENT CONTROL: Version: 4 Ratified by: Corporate Policy Panel Date ratified: 20 July 2017 Name of originator/author: HR Manager Name of responsible

More information

L2C IN NYC RYAN WHITE PART A PLANNING COUNCIL INTEGRATION OF CARE COMMITTEE DECEMBER 3 RD, DECEMBER 17 TH 2014

L2C IN NYC RYAN WHITE PART A PLANNING COUNCIL INTEGRATION OF CARE COMMITTEE DECEMBER 3 RD, DECEMBER 17 TH 2014 L2C IN NYC RYAN WHITE PART A PLANNING COUNCIL INTEGRATION OF CARE COMMITTEE DECEMBER 3 RD, DECEMBER 17 TH 2014 LINKAGE TO CARE (L2C) 1. What is it? Why is it important? Definitions Engagement in Care Continuum

More information

Differentiated Care for Antiretroviral Therapy for Key Populations: Case Examples from the LINKAGES Project

Differentiated Care for Antiretroviral Therapy for Key Populations: Case Examples from the LINKAGES Project Differentiated Care for Antiretroviral Therapy for Key Populations: Case Examples from the LINKAGES Project NOVEMBER 2017 An estimated 37 million people are living with HIV today. A response to the need

More information

Ask the Experts: Managing Lipid Levels

Ask the Experts: Managing Lipid Levels From The Positive Side, Winter 2013 Ask the Experts: Managing Lipid Levels My doctor said that my lipid levels are cause for concern. Any do s and don ts you can share? JB, Brandon, Manitoba Interviews

More information

2016 Social Service Funding Application Non-Alcohol Funds

2016 Social Service Funding Application Non-Alcohol Funds 2016 Social Service Funding Application Non-Alcohol Funds Applications for 2016 funding must be complete and submitted electronically to the City Manager s Office at ctoomay@lawrenceks.org by 5:00 pm on

More information

Diane Lockman, Public Health Nurse. Marilyn Mitchell, Registered Nurse. Sue Mulhall, Public Health Nurse

Diane Lockman, Public Health Nurse. Marilyn Mitchell, Registered Nurse. Sue Mulhall, Public Health Nurse Diane Lockman, Public Health Nurse Marilyn Mitchell, Registered Nurse Sue Mulhall, Public Health Nurse Agenda Pre-evaluation Minimizing Your Risk Emergency Service Worker Exposures Scenarios Questions

More information

Retention in HIV Care

Retention in HIV Care Retention in HIV Care Interpretation, interventions, & identifying those in need of support. Beverly Woodward, MSN, RN Division of Infectious Diseases Vanderbilt University Medical Center Objectives Why

More information

CDC s Role in Outbreak Investigations in Dental Settings

CDC s Role in Outbreak Investigations in Dental Settings CDC s Role in Outbreak Investigations in Dental Settings Jennifer L. Cleveland, DDS, MPH Division of Oral Health OSAP June 14, 2013 National Center for Chronic Disease Prevention and Health Promotion Division

More information

HIV/AIDS MEASURES GROUP OVERVIEW

HIV/AIDS MEASURES GROUP OVERVIEW 2014 PQRS OPTIONS F MEASURES GROUPS: HIV/AIDS MEASURES GROUP OVERVIEW 2014 PQRS MEASURES IN HIV/AIDS MEASURES GROUP: #159. HIV/AIDS: CD4+ Cell Count or CD4+ Percentage Performed #160. HIV/AIDS: Pneumocystis

More information

Measure #340 (NQF 2079): HIV Medical Visit Frequency - National Quality Strategy Domain: Efficiency And Cost Reduction

Measure #340 (NQF 2079): HIV Medical Visit Frequency - National Quality Strategy Domain: Efficiency And Cost Reduction Measure #340 (NQF 2079): HIV Medical Visit Frequency - National Quality Strategy Domain: Efficiency And Cost Reduction 2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process DESCRIPTION:

More information

Toxoplasmosis FACT SHEET. What is toxoplasmosis? Symptoms CONTACT US. Published 2016

Toxoplasmosis FACT SHEET. What is toxoplasmosis? Symptoms CONTACT US. Published 2016 Toxoplasmosis What is toxoplasmosis? Toxoplasmosis is an infection caused by the parasite Toxoplasma gondii (T. gondii). The parasite is transmitted to people through eating undercooked meat, especially

More information

Implementation Science: Evidence to Action. Wafaa El-Sadr, MD, MPH, MPA ICAP at Columbia University

Implementation Science: Evidence to Action. Wafaa El-Sadr, MD, MPH, MPA ICAP at Columbia University Implementation Science: Evidence to Action Wafaa El-Sadr, MD, MPH, MPA ICAP at Columbia University Outline Achievements and challenges in HIV response Knowledge-impact gap (Know-do gap) Research pathway

More information